Physician profile
Li Liu
NPI 1487064341
$7,684.56
in general payments reported to CMS, 2019-2025
49 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $331 · 2021: $1,136 · 2022: $1,342 · 2023: $1,639 · 2024: $1,553 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,875.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,733.83 | 2021-2025 | |
| Ucb, INC. | $998.79 | 2020-2025 | Briviact, Nayzilam, Rystiggo |
| Eisai INC. | $345.98 | 2024-2025 | |
| Pfizer INC. | $301.63 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $299.47 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $272.16 | 2020-2025 | Mavenclad |
| Upsher-Smith Laboratories LLC | $232.58 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $230.09 | 2021-2022 | |
| Lilly USA, LLC | $227.65 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Neurocrine Biosciences, INC. | $222.63 | 2023-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $210.94 | 2023-2025 | |
| Amgen INC. | $204.70 | 2020-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $197.74 | 2020-2021 | |
| Neurelis, INC. | $179.61 | 2023-2025 | Valtoco |
| Novo Nordisk INC | $125.00 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.